Chirurgia (Bucur). 2021 Dec;116(5 Suppl):S7-S14. doi: 10.21614/chirurgia.116.5.suppl.S7.
Ductal carcinoma in situ (DCIS) of the breast is a heterogenous disease and its natural history cannot be directly observed as surgical removal is part of the current standard of care. Studies of incompletely excised breast lesions that were considered benign after biopsy, but at review years later were recognized as DCIS, offers some insight to the natural history of DCIS. Summarizing these retrospective data; 14-53 % of the cases retrospectively diagnosed as DCIS progressed to invasive breast cancer (IBC) during follow-up. While observations from retrospective re-evaluation of biopsies and autopsies adds epidemiological input for understanding the natural history of DCIS, the most important results are still awaited from the ongoing prospective studies on active surveillance of DCIS. These studies with collected data on patient characteristics, life-style and environmental factors, as well as tumor and stromal metabolomics and genomics, will probably further elucidate the natural history of DCIS and how the disease should be treated in the future.
乳腺导管原位癌 (DCIS) 是一种异质性疾病，其自然病程无法直接观察，因为手术切除是目前标准治疗的一部分。对经活检后认为良性但在随后几年复查时被确认为 DCIS 的未完全切除的乳腺病变的研究，为 DCIS 的自然病程提供了一些见解。总结这些回顾性数据；在随访期间，有 14-53% 的病例经回顾性诊断为 DCIS 进展为浸润性乳腺癌 (IBC)。虽然对活检和尸检的回顾性重新评估的观察结果为了解 DCIS 的自然病程提供了流行病学依据，但仍需等待正在进行的 DCIS 主动监测的前瞻性研究的最重要结果。这些研究收集了有关患者特征、生活方式和环境因素以及肿瘤和基质代谢组学和基因组学的数据，可能会进一步阐明 DCIS 的自然病程以及将来如何治疗这种疾病。
